



**GENE THERAPY FORUM**


OCTOBER 7-9, 2026 | BOSTON, USA



**THE 4<sup>th</sup> INTERNATIONAL**

# **HUMAN GENE THERAPY CONFERENCE 2026**

**OCTOBER 7-9, 2026 | BOSTON**



[www.genetherapyconference.com](http://www.genetherapyconference.com)

## CONFERENCE CHAIR



### **Rajiv Gangurde, Phd**

Vice President  
Technical Operations, Gene Therapy  
Parexel, USA

## COMMITTEE



### **Tristan Jervis**

Founder and Managing  
Director, Impact Shine  
Communications, UK



### **Anis Khimani, Ph.D**

Senior Manager  
Global Product Management  
Antylia Scientific, USA



### **Mihir N. Shukla**

Founder & CEO  
Biopharma Consulting Solutions  
LLC, USA



### **Christopher A Bravery PhD**

Consulting Regulatory  
Scientist & Director  
Advanced Biologicals, UK

# WELCOME TO THE 4<sup>th</sup> INTERNATIONAL HUMAN GENE THERAPY CONFERENCE 2026

We are thrilled to announce **Gene Therapy Forum 2026**, the sequel to the highly successful **Gene Forum 2024** and **2022** conferences.

A cordial invitation is extended to you as we embark on this transformative journey. Gene Therapy Forum 2026 is a meticulously curated event designed to illuminate the panorama of gene therapy, not just in the USA, but on a global scale. Our objective is to foster collaboration among pivotal figures in gene therapy—bringing together researchers, industry leaders, and collaborators from around the world.

The conference aspires to unite influential figures in the gene therapy sector, including leading academic scientists, researchers, and market holders. It offers an invaluable platform for the exchange of groundbreaking findings and emerging trends in gene therapy—a field poised to revolutionize healthcare by addressing genetic disorders and advancing personalized medicine.

Gene Therapy Forum 2026 is uniquely tailored to provide actionable insights, expert guidance, peer networking, and assessments from solution providers. The experience promises to be both unforgettable and transformative, empowering you and your organization to reach new heights in addressing critical healthcare priorities. This event offers a chance to showcase innovations and connect with industry leaders, reinforcing the importance of collaboration.

The significance of gene therapy in revolutionizing medical care and addressing genetic challenges cannot be overstated. Standing at the forefront of medical innovation, gene therapy has the potential to create profound impacts globally. Despite the challenges, breakthroughs in treating genetic conditions require collaboration, shared knowledge, and collective effort.

Gene Therapy Forum 2026 will provide an exceptional platform to explore the latest advancements, engage in discussions, and share ideas. The summit will host thought-provoking sessions that foster meaningful interactions and collaborations.

**Secure your place early at Gene Therapy Forum 2026, where we anticipate a surge in interest.** Register now to be part of this premier interdisciplinary platform for researchers, practitioners and educators who are shaping the future of gene therapy. We believe in the power of collective effort and the success of **Gene Forum 2024** showcased how impactful active participation can be. Regardless of where you stand in the gene therapy value chain, your voice matters, and we invite you to join us at **Gene Therapy Forum 2026**.

## WHY TO ATTEND?

- Understand Current Market Trends
- Navigate Regulatory Frameworks
- Explore Investment and Funding Strategies
- Optimize Manufacturing and Supply Chain Practices
- Enhance Clinical Trial Design and Execution
- Stay Updated on Technological Innovations
- Build Successful Collaborations and Partnerships
- Develop Effective Commercialization Strategies
- Navigate Ethical and Societal Considerations
- Master Post-Market Surveillance and Real-World Evidence

## WHO WILL YOU MEET?

### INDUSTRY

- Manufacturing
- Product Development
- Quality
- Value & Market Access
- Therapy Administration
- Research & Development
- Regulatory Affairs
- Vector Systems Engineering
- Laboratory
- Science
- Information Technology
- Validation
- Training
- Clinical
- Patient Advocacy

### JOB ROLE

- Scientist
- Executive and Mid-Level Management
- Project Management
- Technical Services
- Supply Chain
- Manufacturing
- Application
- Risk Management
- Patient Monitoring
- Customer Engagement
- Marketing and Sales
- Clinical Strategy Pharmacist
- Product Communications
- Clinical Research
- Post Doc, Ph.D. Student

# USA Gene Therapy Market

The **Gene Therapy Market in the USA** is intricately segmented by indication, including cancer, genetic disorders, metabolic diseases, cardiovascular diseases, spinal muscular atrophy (SMA), eye disorders, and others. This refined classification provides a clear understanding of the diverse therapeutic applications being pursued in the region. Additionally, the market is delineated by technology, encompassing various advanced gene delivery systems such as **Adeno Virus Vectors, Adeno-Associated Virus (AAV) Vectors, Lentiviral Vectors, Retroviral Vectors, and CRISPR/Cas9** gene editing technologies, among other innovative approaches.

Geographically, the U.S. market is a key player within the North American region, which is considered the leader in gene therapy development and commercialization. This strategic segmentation equips stakeholders with valuable insights into the rapidly evolving landscape of gene therapies, enabling informed decision-making and targeted analyses.

The USA gene therapy market is witnessing a surge in product launches and technological advancements. **Recent innovations** in gene editing technologies, including CRISPR, and the development of novel vector designs, have significantly accelerated the progress of gene therapy products. The market is projected to see strong revenue growth, with global gene therapy revenues in the U.S. expected to increase from **\$9.5 billion** in 2023 to approximately **\$24.5 billion** by 2028, representing an impressive **CAGR of 32%**, particularly in the fields of **oncology** and **genetic disorders**.

Strategic partnerships, joint ventures, and collaborations between industry giants and emerging biotech firms are pivotal in securing the necessary investments and funding to fuel further advancements in gene therapy. Notable partnerships, such as **Vertex Pharmaceuticals** and **Bluebird Bio's** collaboration for gene editing therapies targeting **Sickle cell disease and beta-thalassemia** reflect the growing strength of the market.

The **FDA approvals** in recent years have been a significant catalyst in advancing the gene therapy sector in the USA. Products like **Zolgensma**, for spinal muscular atrophy, and **Luxturna**, for inherited retinal diseases, have set the stage for other groundbreaking therapies. In 2023, the **FDA** also granted fast-track designations to therapies targeting **Rett Syndrome** and **Huntington's Disease**, adding momentum to the growing field. Furthermore, recent approvals such as **Vyjuvek** for **DEB** (Dystrophic Epidermolysis Bullosa) and **Elevidys** for **Duchenne Muscular Dystrophy (DMD)** underscore the industry's commitment to addressing unmet medical needs.

# **RESETTING THE GENETIC BUTTON: QUALITY AND REGULATORY REQUIREMENTS**

## **SESSION 1: GENE THERAPY REGULATORY LANDSCAPE**

As gene therapy progresses from experimental innovation to therapeutic reality, navigating the complex and evolving regulatory environment is critical. This session will provide a comprehensive overview of the global regulatory frameworks that govern gene therapy development, approval, and post-market surveillance. Participants will gain insights into how regulators are approaching safety, efficacy, and long-term monitoring, and how companies can align their strategies for successful product approval and commercialization.

### **POTENTIAL SPEAKERS**

- U.S. Food and Drug Administration (FDA)
- European Medicines Agency (EMA)
- Medicines and Healthcare products Regulatory Agency (MHRA)
- European Liver Patients' Association (ELPA)
- BioPharma Global

## **SESSION 2: BENEFITS, RISKS AND APPLICATIONS OF GENE THERAPY**

Gene therapy presents a powerful approach to treating genetic and acquired diseases by targeting their root causes. This session will explore key benefits, emerging applications, and associated risks—including regulatory, ethical, and safety considerations. Through case studies and new delivery strategies, attendees will gain insights into the current and future impact of gene therapy in clinical practice.

### **POTENTIAL SPEAKERS**

- CRISPR Therapeutics
- Bluebird bio
- Intellia Therapeutics
- Sangamo Therapeutics
- Editas Medicine

## SESSION 3: WORLDWIDE APPROVED AND SUCCESSFULLY RUNNING CELL AND GENE THERAPIES (CGTS)

The global gene and cell therapy (CGT) landscape is rapidly expanding, with numerous therapies now approved and demonstrating real-world impact across various therapeutic areas. This session will spotlight the most successful and clinically validated CGTs approved across major regulatory markets. Attendees will gain a deep understanding of what has driven these therapies from development to durable patient benefit, and what lessons can be applied to emerging programs.

### POTENTIAL SPEAKERS

- Vertex Pharmaceuticals
- Novartis Gene Therapies
- Sarepta Therapeutics
- Adaptimmune Therapeutics
- Juno Therapeutics
- Gritstone Oncology

## SESSION 4: QUALITY STANDARDS IN GENE THERAPY: GLP, GMP, AND COMPLIANCE FRAMEWORKS

Ensuring product integrity, safety, and regulatory compliance is critical to the success of gene therapy development and commercialization. This session will delve into the evolving roles of **Quality Assurance (QA)** and **Quality Control (QC)** in the manufacturing and release of gene therapy products, with a focus on challenges unique to these complex biologics.

### POTENTIAL SPEAKERS

- AskBio (Bayer subsidiary)
- REGENXBIO
- Pfizer Gene Therapy Division
- Avance Biosciences
- Svar Life Science AB

## SESSION 5: SAFETY, EFFICACY, RISK MANAGEMENT AND PHARMACOVIGILANCE IN CGT

This session will delve into critical aspects of safety and efficacy in cell and gene therapy, with a focus on risk management and pharmacovigilance. Experts will discuss strategies for monitoring adverse events, ensuring long-term patient safety, and navigating regulatory expectations to support the responsible development and deployment of CGT therapies.

### POTENTIAL SPEAKERS

- Parexel
- IQVIA
- Symogen
- Fortrea
- Signal Pharma

## SESSION 6: ETHICAL AND SOCIETAL CONSIDERATIONS

This session will explore the ethical and societal implications of gene therapy, including issues of equity, informed consent, access, and long-term impact on patients and communities. Experts will examine how advances in gene therapy intersect with public values and expectations, aiming to foster responsible innovation that aligns with societal needs and ethical standards.

### POTENTIAL SPEAKERS

- Harvard Medical School – Bioethics Program
- Alacrita
- CBER (Center for Biologics Evaluation and Research)
- NIH (National Institutes of Health)
- Alliance for Regenerative Medicine (ARM)

# RE-ENGINEERING AND REWRITING GENETICS WITH GENE THERAPY: PAST, PRESENT, FUTURE APPROACHES

## SESSION 1: GENE THERAPY DEVELOPMENT AND METHODS

This session will explore the critical stages and innovative techniques involved in the development of gene therapies—from early discovery to clinical application. As the gene therapy field continues to evolve, understanding the underlying methodologies and translational strategies is essential for ensuring safe, effective, and scalable therapies.

### POTENTIAL SPEAKERS

- Rocket Pharmaceuticals
- Verve Therapeutics
- Poseida Therapeutics
- Adverum Biotechnologies
- Orchard Therapeutics

## SESSION 2: GENE THERAPY R&D ACCELERATION BY AI

Artificial Intelligence (AI) is transforming the landscape of gene therapy research and development. This session will delve into how AI-driven tools and platforms are accelerating the discovery, design, testing, and optimization of gene therapy products—making the development pipeline more efficient, predictive, and precise.

### POTENTIAL SPEAKERS

- bit.bio
- Carina Biotech
- Dyno Therapeutics
- Elixirgen Scientific
- REVVITY

### SESSION 3: DNA & RNA-BASED TECHNOLOGIES

DNA and RNA-based technologies are at the forefront of innovation in gene therapy, offering transformative approaches for treating a wide range of genetic and acquired diseases. This session will highlight the latest advancements, methodologies, and clinical applications of nucleic acid-based therapeutics, including their role in gene editing, expression modulation, and next-generation delivery platforms.

#### POTENTIAL SPEAKERS

- Anjarium Biosciences
- Laverock Therapeutics
- Siren Biotechnology
- Beam Therapeutics
- Evox Therapeutics

### SESSION 4: GENE THERAPY CLINICAL TRIALS AND PATIENT ENGAGEMENT

As gene therapies advance from the lab to the clinic, the success of clinical trials depends not only on scientific rigor but also on meaningful patient engagement. This session will explore the evolving landscape of clinical trial design for gene therapies, with a focus on regulatory expectations, trial execution, and strategies to engage, inform, and support patients throughout their participation.

#### POTENTIAL SPEAKERS

- ASTCT (American Society for Transplantation and Cellular Therapy)
- European Liver Patients' Association (ELPA)
- University of Florida
- Lonza
- SK pharmteco

## SESSION 5: GENE DRUG DELIVERY AND RECENT GENE EDITING TECHNOLOGIES

This session will highlight recent innovations in gene delivery systems and cutting-edge gene editing tools such as CRISPR and base editing. Experts will discuss their applications, efficiency, and precision, along with challenges in targeting, safety, and scalability—providing insights into how these technologies are shaping the future of gene-based therapies.

### POTENTIAL SPEAKERS

- Envoya, Inc
- Janssen Biotech
- Engelex
- Scribe Therapeutics
- Editas Medicine

## SESSION 6: GENE THERAPY SUCCESSES AND ONGOING RESEARCH

This session will showcase notable successes in gene therapy across various disease areas, emphasizing real-world impact and clinical outcomes. It will also highlight ongoing research efforts aimed at expanding therapeutic targets, improving delivery methods, and enhancing safety and durability. Attendees will gain insight into the current progress and future potential of gene therapy innovations.

### POTENTIAL SPEAKERS

- FUJIFILM Cellular Dynamics
- Bayer
- Mayo Clinic
- CSL Behring
- NIH (National Institutes of Health)

## PANEL DISCUSSION 1

### **SAFEGUARDING PURITY: TACKLING CONTAMINATION CHALLENGES IN AAV CAPSID PRODUCTION AND DISTRIBUTION**

This session will highlight recent innovations in gene delivery systems and cutting-edge gene editing tools such as CRISPR and base editing. Experts will discuss their applications, efficiency, and precision, along with challenges in targeting, safety, and scalability—providing insights into how these technologies are shaping the future of gene-based therapies.

## POTENTIAL PANELIST

- Affinia Therapeutics
- AskBio
- Capsida Biotherapeutics
- BridgeBio Gene Therapy
- rAAVen Therapeutics

## PANEL DISCUSSION 2

### **BREAKTHROUGH BIOTECH: APPROVED CELL AND GENE THERAPIES AND WHAT LIES AHEAD**

This panel highlights globally approved cell and gene therapies (CGTs) that are redefining standards in precision medicine, from rare genetic conditions to cancer. Experts from industry, regulatory, and biotech sectors will discuss key factors behind these successes and examine emerging therapies on the horizon. The discussion will also tackle critical challenges such as scalability, affordability, long-term safety, and equitable global access.

## POTENTIAL PANELIST

- Paraxel
- Novartis
- Spark Therapeutics
- Bluebird Bio
- CRISPR Therapeutics
- Rocket Pharmaceuticals

**DAY- 2, 8<sup>th</sup> OCTOBER, 2026**

# **UNLOCKING HEALTH MYSTERIES: ANALYTICS MANUFACTURING AND COMMERCIALIZATION STRATEGIES**

## **SESSION 1: MARKET ANALYSIS, TRENDS, AND OPPORTUNITIES IN GENE THERAPY**

The gene therapy market is evolving rapidly, with increasing approvals, rising investment, and expanding therapeutic applications. This session provides a comprehensive look at the current and future state of the global gene therapy market, highlighting key trends, investment patterns, and strategic opportunities for growth and innovation.

### **POTENTIAL SPEAKERS**

- Miles Payer Strategy
- Barbara Ryan Advisors
- Pharmerit International
- Envision Pharma Group
- ZS

## **SESSION 2: INVESTMENTS, PARTNERSHIPS AND FUNDINGS ON GLOBAL SCALE**

This session explores the evolving global investment landscape in gene therapy, highlighting key funding trends, venture capital flows, and strategic collaborations. Attendees will gain insights into how financial partnerships among startups, pharma companies, and public institutions are accelerating innovation, from early research to commercialization, and shaping the future of gene and cell therapies worldwide.

### **POTENTIAL SPEAKERS**

- Deerfield Management
- RA Capital Management
- ARCH Venture Partners
- Lauxera Capital Partners
- Third Rock Ventures
- Symbiosis Capital Management
- Signet Healthcare Partners
- RBC Capital Markets

## SESSION 3: LOGISTICS, SUPPLY CHAIN, COST OPTIMIZATION, AND AFFORDABILITY IN GENE THERAPY

Gene therapies pose unique logistical and economic challenges due to their complex manufacturing processes, time-sensitive handling requirements, and high development costs. This session will explore the critical infrastructure behind the successful delivery of gene therapies—from raw material sourcing to last-mile patient administration—while also addressing strategies for cost optimization and improving affordability for healthcare systems and patients.

### POTENTIAL SPEAKERS

- TrakCel
- Catalent
- Bristol Myers Squibb (BMS)
- Lonza
- Accenture

## SESSION 4: ANALYTICAL PROCESS DEVELOPMENT AND SCALE-UP TECHNOLOGIES

This session will delve into analytical process development and scale-up technologies critical to advancing gene therapy from bench to bedside. It will cover strategies for optimizing process efficiency, ensuring product quality, and meeting regulatory standards during scale-up. Attendees will explore innovations enabling robust, reproducible manufacturing of gene therapies for clinical and commercial applications.

### POTENTIAL SPEAKERS

- BioMarin
- 4basebio
- Outpace Bio
- Galapagos
- Thermo Fisher Scientific

## SESSION 5: PRICING STRATEGIES, MARKET ACCESS, COMMERCIALIZATION AND REIMBURSEMENT IPR'S AND LICENSING

This session will examine key factors influencing the commercialization of gene therapies, including pricing strategies, market access, and reimbursement models. It will also address intellectual property rights (IPRs) and licensing frameworks that shape competitive dynamics and innovation incentives. Attendees will gain a comprehensive view of how value is defined and delivered in this rapidly evolving therapeutic landscape.

### POTENTIAL SPEAKERS

- Arvato Supply Chain Solutions SE
- Yourway Biopharma Services Company
- Cryoport
- XPO Logistics
- BD Biosciences
- SternAegis
- Eric Del Balso

**DAY- 3, 9<sup>TH</sup> OCTOBER, 2026**

# **GENE THERAPEUTICS: CLINICAL APPROACHES AND APPLICATION**

## **SESSION 1: COMBINED GENE AND CELLULAR THERAPY APPROACHES FOR CANCER TREATMENT AND IMMUNOTHERAPIES**

This session explores how the combination of gene therapy and cellular immunotherapy is transforming cancer treatment. It highlights advances in engineered immune cells, gene editing, and CAR-T/NK therapies that enhance specificity, overcome tumor resistance, and improve patient outcomes. Experts will share the latest research and clinical insights driving this innovative approach in cancer immunotherapy.

### **POTENTIAL SPEAKERS**

- University of Pennsylvania
- Precigen
- Allarta Life Science
- AstraZeneca
- Allogene Therapeutics
- Stealth BioTherapeutics

## **SESSION 2: CGT APPROACHES FOR HIV-AIDS, PULMONARY DISORDERS, AND GENETIC DISEASES**

This session highlights recent advances in cell and gene therapy (CGT) for diseases like HIV-AIDS, pulmonary disorders, and inherited conditions such as sickle cell anaemia, cystic fibrosis, haemophilia, and diabetes. Experts will discuss targeted therapies, delivery techniques, and clinical progress, showcasing how CGT is tackling key challenges to offer lasting, potentially curative treatments.

## POTENTIAL SPEAKERS

- University of Southern California (USC)
- Fred Hutchinson Cancer Center
- Kiji Therapeutics
- Dana Farber
- Myeloid Therapeutics

## SESSION 3: GENE THERAPY FOR NEURODEGENERATIVE AND RARE DISORDERS

This session highlights the potential of gene therapy to treat neurodegenerative and rare genetic disorders. It covers innovative delivery methods to the central nervous system and reviews clinical progress in diseases like spinal muscular atrophy, Huntington's, Parkinson's and Batten disease. Experts will discuss advances in vector design and administration techniques aimed at slowing or reversing disease progression.

## POTENTIAL SPEAKERS

- Biogen
- Pfizer
- Genentech (Roche)
- AveXis
- Neurogenesis Bio

## SESSION 4: EMERGING GENETIC DISORDER THERAPIES AND NEXT-GENERATION SEQUENCING (NGS) ADVANCES

This session covers recent advances in gene and cell therapies for genetic disorders, alongside the transformative impact of next-generation sequencing (NGS) on diagnosis and personalized treatment. Experts will highlight how integrating NGS with therapy development accelerates discovery, enables biomarker identification, and guides the creation of targeted gene therapies.

## POTENTIAL SPEAKERS

- Illumina
- Harvard Medical School
- Code Bio Therapeutics
- 10x Genomics
- ArcticZymes

## SESSION 5: GENE THERAPY FOR OPHTHALMIC AND MUSCULAR DISORDERS

This session explores cutting-edge gene therapy approaches targeting ophthalmic and muscular disorders. By addressing genetic defects at their root, these therapies offer promising treatments for conditions like retinitis pigmentosa and Duchenne muscular dystrophy, potentially restoring function and halting disease progression. We'll examine recent breakthroughs, delivery methods, and clinical trial outcomes shaping the future of personalized medicine in these fields.

### POTENTIAL SPEAKERS

- Aurion Biotech
- Cellino
- Ray Therapeutics
- Satellite Bio
- FUJIFILM Cellular Dynamics

## SESSION 6: BIO REVOLUTION UNITING 3D BIOPRINTING AND GENE THERAPY FOR TOMORROW'S HEALTHCARE

This session delves into the powerful convergence of 3D bioprinting and gene therapy, revolutionizing regenerative medicine and personalized healthcare. By combining precise tissue engineering with genetic interventions, we explore innovative solutions for repairing, replacing, and enhancing human tissues. Join us to discover how this bio revolution is shaping the future of therapeutic development and patient care.

### POTENTIAL SPEAKERS

- Organovo
- BICO Group (formerly Cellink)
- CRISPR Therapeutics

### PANEL DISCUSSION 3

#### **BRINGING CELL THERAPY TO THE PEOPLE: DELIVERING IN THE COMMUNITY, FOR THE COMMUNITY**

This panel gathers experts to discuss how gene and cell therapies can reach patients in local communities. They will address challenges like infrastructure, regulations, costs, and patient awareness. The conversation will cover scalable production, community treatment centers, and partnerships to support local healthcare providers, with a focus on making these therapies accessible and inclusive for all patients.

#### **POTENTIAL PANELIST**

- CureLGMD2i Foundation
- Allen Institute
- Alliance for Regenerative Medicine
- ARMI (Advanced Regenerative Manufacturing Institute)
- Battelle Memorial Institute
- BioBridge Global

### PANEL DISCUSSION 4

#### **ACCELERATING INNOVATION THROUGH REGULATORY CONVERGENCE IN CELL AND GENE THERAPY**

This panel gathers experts to discuss how aligning regulatory rules across countries can speed up the development and approval of cell and gene therapies. They will talk about reducing repetitive work, simplifying clinical trials, and improving global access to treatments. The discussion will cover challenges and successful examples of collaboration to create a more unified and efficient regulatory process that benefits innovation and patient safety.

#### **POTENTIAL PANELIST**

- FDA
- WHO
- EMA
- NIH
- MHRA

# SPONSORSHIP OPPORTUNITIES

Join as a sponsor and be recognized as a leader in the global innovation community in Gene Therapy

## GOLD SPONSOR-10000 USD

- An exhibition booth space of 20\*10 ft in the exhibiting area.
- One table and two chairs.
- Three complimentary delegate registrations for the employees of sponsoring organization.
- Logo prominently displayed as a gold sponsor on the meeting banner.
- One full-page color advertisement with prime positioning in the conference program.
- Logo displayed and hyperlinked to the organization webpage.
- Acknowledgment as a Gold sponsor during the opening and closing ceremony.
- Speaker opportunity in the conference program.
- One promotional brochure to be inserted in each satchel.

## SILVER SPONSOR-7000 USD

- An exhibition booth space of 10\*10 ft in the exhibiting area.
- One table and two chairs.
- Two complimentary delegate registrations for the employees of sponsoring organization.
- Logo prominently displayed as a silver sponsor on the meeting banner.
- One full-page colour advertisement with prime positioning in the conference.
- Logo displayed and hyperlinked to the organization webpage.
- Acknowledgment as a silver sponsor during the opening and closing ceremony.
- Speaker opportunity in the conference program.
- Logo displayed on the conference homepage and all printed materials.
- One promotional brochure to be inserted in each satchel.

## BRONZE SPONSOR-5000 USD

- An exhibition booth space of 10\*10 ft in the exhibiting area.
- One complimentary delegate registration for the employees of the sponsoring organization.
- One table and one chair.
- Logo prominently displayed as a bronze sponsor on the meeting banner.
- One half-page color advertisement in the conference program (to be distributed to all participants)
- Logo displayed and hyperlinked to the organization's webpage.
- Acknowledgment as a Bronze sponsor during the opening and closing ceremonies.
- Speaker opportunity in the conference program.
- Logo displayed on the conference homepage and all printed materials.

**IF YOU DO NOT SEE A SPONSORSHIP  
THAT SUITS YOU OR YOUR BUDGET  
THEN SPEAK WITH US-WE ARE OPEN  
TO INNOVATIVE SOLUTIONS**

### Contact Information

[writeus@scientificprism.com](mailto:writeus@scientificprism.com)  
+61390163202

# EXHIBITION OPPORTUNITIES

Gene Therapy Forum 2026 is an exciting opportunity to showcase to a broader international audience. Any new technology and new products from, and or the services your industry or company may offer. As an exhibitor, you will access the corporate executives, researchers, and commercialization leadership who rely on your products and services to develop their new technologies.

## EXHIBITOR BENEFITS AND INCLUSIONS-4000 USD

- An exhibition booth space of 10\*6 ft in the exhibiting area.
- One table and one chair.
- One complimentary pass and access to the exhibition booth and networking.
- Publication of the exhibitor profile in the souvenir.
- Logo displayed and hyperlinked to the organization's webpage.

## SHOWCASE BOOTH-2500 USD

Industry prospectors are looking for breakthrough technologies that are ready for licensing, corporate partnering, or investment opportunities. This can include prototypes, demonstrations, and display booths to showcase your innovative solutions at Gene Forum 2026.

## MARKETING AND PROMOTIONAL OPPORTUNITIES

Gene Therapy Forum 2026 offers various marketing and promotional opportunities for corporate companies. MPOs are an effective way to raise your company's visibility, effectively get your message and brand out to a targeted audience, generate more sales opportunities, and increase the event's ROI. History has shown that companies that utilize MPOs generate more booth traffic, more sales leads, and an overall higher level of satisfaction than companies that do not take advantage of these opportunities.

- Lunch/cocktail sponsor
- Coffee break sponsor
- Keynote/oral sessions sponsor
- Conference delegate bag sponsor
- Bag insert sponsor
- Lanyard sponsor
- Notepad sponsor

# PARTICIPATION FORMATS

Choose suitable options to get maximum benefits:



## DELEGATE PARTICIPATION

- 1 delegate pass
- Access to all conference sessions
- Access to workshops/symposiums
- Access to exhibitor/sponsor booths
- Conference materials
- Lunch/breaks during the conference days
- Opportunity to invite attendees to one-to-one meetings
- Post-conference materials



## SPEAKER OPPORTUNITY

- Speaker slot in the program
- Access to all conference sessions
- Access to workshops/symposiums
- Access to exhibitor/sponsor booths
- Conference materials
- Lunch/breaks during the conference days
- Post-conference materials
- Branding package



## EXHIBITION BOOTH SPACE

- 1 delegate pass
- 10\*6 ft exhibition booth space
- Access to all conference sessions
- Access to workshops/symposiums
- Access to exhibitor/sponsor booths
- Conference materials
- Lunch/breaks during the conference days
- Post-conference materials
- Exclusive branding package



## SPONSORSHIP OPPORTUNITIES

- Extended number of delegate passes
- Speaker slot in the program
- Prescheduled one-to-one meetings
- Access to all conference sessions
- Access to workshops/symposiums
- Access to exhibitor/sponsor booths
- Conference materials
- Lunch/breaks during the conference days
- Post-conference materials
- Exclusive branding package

# REGISTRATION

Revolutionize the future of medicine! Join us at the forefront of innovation for the 4<sup>th</sup> International Human Gene Therapy Conference. Secure your seat and be part of groundbreaking discoveries that will shape tomorrow's healthcare landscape. Don't just spectate, participate! Reserve your spot today and be empowered to make a difference in the world of gene therapy. Elevate your understanding, expand your network, and ignite your passion for cutting-edge science. Time is ticking; register now and unlock the potential of gene therapy.

- Abstract Submission Date ends on **31 June, 2026**
- Early Bird Registration ends on **01 July, 2026**
- Standard Registration ends on **01 October, 2026**

## EARLY BIRD REGISTRATION

Ends on July 01, 2026

THERAPEUTIC DEVELOPER

**USD 1099**

STUDENT

**USD 549**

ACADEMIC & NON-PROFITS

**USD 890**

SERVICE & TOOL PROVIDERS

**USD 1190**

EXHIBITION BOOTH SPACE

**USD 4000**

ONLINE TALK

**USD 300**

## STANDARD REGISTRATION

Ends on October 01, 2026

THERAPEUTIC DEVELOPER

**USD 1399**

STUDENT

**USD 699**

ACADEMIC & NON-PROFITS

**USD 1090**

SERVICE & TOOL PROVIDERS

**USD 1390**

EXHIBITION BOOTH SPACE

**USD 4200**

ONLINE TALK

**USD 350**



**GENE THERAPY FORUM**

OCTOBER 7-9, 2026 | BOSTON, USA

# SEE YOU ALL IN BOSTON, USA FOR THE 4<sup>th</sup> INTERNATIONAL HUMAN GENE THERAPY CONFERENCE AND EXHIBITION



**PRISM**

**Anjali.S**

Conference Producer

[chairs@genetherapyconference.com](mailto:chairs@genetherapyconference.com)

Australia: +61 390163202

[www.genetherapyconference.com](http://www.genetherapyconference.com)

**Conference Secretariat:**

Prism Scientific Services Pty Ltd [PCO] 302/480

Collins Street, Melbourne VIC 3000, Australia

Website: <https://www.scientificprism.com>